ARK Investment Management LLC and Catherine D. Wood filed Amendment No. 8 to Schedule 13G with the SEC on November 13, 2026, disclosing their beneficial ownership of common stock in Beam Therapeutics Inc. as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: ARK Investment Management LLC and Catherine D. Wood each reported beneficial ownership of 11,805,372 shares of Beam Therapeutics common stock.
  • Percent of class: The 11,805,372 shares represent 11.43% of the outstanding class, according to the filing.
  • ARK sole voting power: ARK reported sole voting power over 11,174,409 shares and shared voting power over 160,825 shares.
  • Catherine D. Wood: Wood reported no sole voting or dispositive power, but shared voting power over 11,335,234 shares and shared dispositive power over all 11,805,372 shares.
  • Notable client interest: The filing states that ARK Innovation ETF, a series of a Delaware statutory trust, is the only ARK client with an interest in these securities exceeding 5 percent.
  • Triggering date: The event requiring the filing occurred on September 30, 2026.

ARK and Wood Disclose 11.43% Stake in Beam Therapeutics via Amendment No. 8

ARK Investment Management LLC, organized in Delaware, and Catherine D. Wood, a United States citizen, jointly filed Amendment No. 8 to Schedule 13G with the SEC on November 13, 2026. The filing covers common stock of Beam Therapeutics Inc. (NASDAQ:BEAM), CUSIP 07373V105, whose principal executive offices are located at 238 Main Street, Cambridge, MA 02142. Both filers share a business address at 200 Central Avenue, St. Petersburg, FL 33701.

According to the filing, ARK holds sole dispositive power over all 11,805,372 shares, while Wood holds shared dispositive power over the same aggregate amount and no sole dispositive power. For voting purposes, ARK retains sole voting power over 11,174,409 shares and shared voting power over 160,825 shares. Wood, classified as a holding company and individual (HC, IN), holds no sole voting power but shared voting power over 11,335,234 shares. ARK is classified as an investment adviser (IA).

The filing notes under Item 6 that "no client of ARK Investment Management LLC currently has an interest in the securities reported herein in excess of 5 percent except ARK Innovation ETF, a series of a Delaware statutory trust." The filers certified that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The filing was signed by Kathleen Fontano, Chief Compliance Officer of ARK, and Catherine D. Wood in her capacity as Chief Executive Officer and Chief Investment Officer.

What Was Disclosed

ARK Investment Management LLC and Catherine D. Wood filed Amendment No. 8 to Schedule 13G reporting combined beneficial ownership of 11,805,372 shares, or 11.43%, of Beam Therapeutics Inc. common stock, with the triggering event dated September 30, 2026.